Use of Multiple Biophysical Technologies in Parallel for a Streamlined Biologics Selection Process
Jan Schnatwinkel, PhD, Application Scientist at NanoTemper Technologies
In the present biologics landscape, there are increasing concerns around ROI on development of protein-based therapeutic candidates. Researchers invest time, resources, and money on candidates that fail once they reach clinic. In order to de-risk the selection process and improve the chances of success, researchers must compile full developability profiles of their candidates and identify those with optimal quality attributes. Learn how Prometheus Panta, a platform for getting high-resolution, high-quality data around thermal and colloidal stability, helps researchers streamline their developability processes, and see how it helped one group at Merck gain more insight into their candidates.
Jan Schnatwinkel is a biochemist, with a PhD from the University of Bochum where he studied interaction mechanisms of intrinsically disordered proteins. As an Application Specialist at NanoTemper Technologies, Jan supports customers with their biologics characterization projects.
